The Status of Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer, Part 2: Extending the Scope Beyond Olaparib and BRCA1/2 Mutations

Abstract: Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have shown clinical activity in epithelial ovarian cancer, leading both the US Food and Drug Administration (FDA) and the […]

The Status of Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer, Part 1: Olaparib

Abstract: Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have shown promising clinical activity in epithelial ovarian cancer. Following the observation in vitro that PARP inhibition is synthetically […]

Neoadjuvant Chemotherapy for Advanced Epithelial Ovarian Cancer

Abstract: The historical standard treatment paradigm for advanced epithelial ovarian cancer is surgical staging followed by adjuvant platinum- and taxane-based chemotherapy. It is well established that […]

New Drugs in Ovarian Cancer

H&O How has the prognosis for ovarian cancer changed in recent years? GF Over the last decade, ovarian cancer prognosis has improved very modestly. According […]